Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Abeona nets $97.2mm via FOPO

Executive Summary

Abeona Therapeutics Inc. (gene and cell therapies) netted $97.2mm in its follow-on public offering of 32.38mm common shares (including the full exercise of the overallotment) at $2.50 each and pre-funded warrants to buy 9.02mm shares at $2.50. The pre-funded warrants were sold to existing shareholder Great Point Partners, which will get two board seats.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Nanotechnology, Chips, etc.
    • Synthesis Technologies, Production Processes
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
      • Site Specific
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies